Gilead Joins Growingly Crowded Protein Degradation Field with Nurix Therapeutics Deal

By Michelle Liu

Pharma Deals Review: Vol 2019 Issue 6 (Table of Contents)

Published: 26 Jun-2019

DOI: 10.3833/pdr.v2019.i6.2437     ISSN: 1756-7874

Section: Research & Development



Continuing its recent deal spree, Gilead Sciences has partnered with Nurix Therapeutics to discover, develop and commercialise a pipeline of targeted protein degradation drugs for the treatment of cancer and other challenging diseases...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details